|Bid||324.46 x 200|
|Ask||324.75 x 100|
|Day's Range||323.84 - 327.37|
|52 Week Range||244.28 - 348.84|
|PE Ratio (TTM)||19.98|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Categories: Fundamental Analysis Yahoo FinanceClick here to see latest analysis Capitalcube gives Biogen, Inc. a score of 88. Our analysis is based on comparing Biogen, Inc. with the following peers – Amgen Inc., Celgene Corporation, Gilead Sciences, Inc., Johnson & Johnson, AbbVie, Inc., Pfizer Inc., Sanofi Sponsored ADR, Acorda Therapeutics, Inc., Sangamo Therapeutics, Inc. and Bio-Rad Laboratories, Inc. Class ... Read more (Read more...)
Michael Gilman, a former Biogen executive known for launching successful biotech startups, has pulled back the curtain on his latest project: a cancer drug developer backed by $49.5 million in financing from GV, Atlas Venture and others. Cambridge-based Obsidian Therapeutics came out of stealth mode on Wednesday, saying that it hopes to create an improved class of cell and gene therapies — so-called “living” drugs that reprogram a person’s immune cells to attack tumors. Obsidian was founded in 2015 by Atlas, which exclusively funded the company’s operations through mid-2017.
Mark Hernon, a former regional IT chief at Takeda Pharmaceuticals, will oversee innovative IT tools that help develop treatments for Alzheimer’s, dementia and other neurological diseases, the biotech firm ...
Categories: ETFs Yahoo FinanceClick here to see latest analysis ETFs with exposure to Biogen, Inc. Here are 5 ETFs with the largest exposure to BIIB-US. Comparing the performance and risk of Biogen, Inc. with the ETFs that have exposure to it gives us some ETF choices that could give us similar returns with lower volatility. Ticker Fund Name ... Read more (Read more...)
Categories: ETFs Yahoo FinanceGet full CapitalCube analysis *Disclaimer : This is as of previous day’s closing price. Technical Indicators Below is a quick look at 5 technical indicators for Biogen, Inc.. More studies are available on the Technical Chart. Indicator Signal Closing Price above/below 50 Day Moving Average Bearish Closing Price above/below 200 Day Moving Average Bullish 50 ... Read more (Read more...)
Sarissa Capital Management last week made nearly $15 million in stock purchases. Sarissa, a hedge fund that specializes in drug developers, added to positions in Biogen (BIIB) and Medicines (MDCO). On Nov. 28 and 29 the fund bought 30,000 shares of Biogen for $9.52 million, or $317.36 each.
The deal will be beneficial for both companies as it will reduce costs and bring in a strong partner for Alkermes.
While there were not too many updates this week, companies like Regeneron (REGN) and Biogen were in the news related to their pipeline.
Shares of Biogen (BIIB) and Alkermes (ALKS) are both higher on Tuesday, after they announced a licensing agreement to develop and commercialize ALKS 8700, a multiple sclerosis treatment. The drug, which ...
Biogen will pay Alkermes up to $228 million to gain another multiple sclerosis asset as key drug Tecfidera faces a patent cliff in the mid-2020s.
In its quest to keep one of its cash cows pumping, biotech giant Biogen (BIIB) has applied a simple lesson: If you can't beat 'em, partner with them. Biogen, of course, makes Tecfidera, a blockbuster treatment that is expected to go off patent sometime in the early 2020's. Leerink's Geoffrey Porges and Bradley Canino explain how the Alkermes deal might help: This morning Biogen issued a press release stating that they had entered into a global licensing agreement with Alkermes (MP) to develop ALKS 8700, a monomethyl fumarate (MMF) pro-drug that is currently in phase III development for relapsing-remitting multiple sclerosis (RRMS). This announcement comes as a surprise, since ALKS 8700 was presumed to be one of several rivals, and risks, to the outlook for Biogen’s Tecfidera.
Meanwhile, retailers like Best Buy (BBY), Gap (GPS) and JCPenney (JCP) are trading higher on some positive early Black Friday results. JCPenney’s website saw the most visits of any day so far this year. Shares of Time Inc. (TIME) are surging after Meredith (MDP) said it struck a deal to buy Time for $1.85 billion in cash, with a little help from the Kochs.
Biogen Inc said on Monday it has licensed Alkermes Plc's multiple sclerosis (MS) drug, further boosting its position in the race for the next treatment amid slowing sales of its own flagship MS drug, Tecfidera. Biogen's deal to buy the rights to develop and market Alkermes' MS drug comes after the drugmaker in January licensed Danish company Forward Pharma A/S's drug patents covering the same condition for $1.25 billion. Sales of Tecfidera, Biogen's bestselling MS drug, has slowed amid stiff competition from Roche AG's Ocrevus and Sanofi SA's Aubagio.
Alkermes and Biogen have inked a pact to develop and commercialize ALKS 8700, which is in Phase 3 development for treating relapsing forms of multiple sclerosis.
Alkermes PLC shares rose 5.8% in premarket trade Monday on news of the company's partnership with Biogen Inc. on the multiple sclerosis drug ALKS 8700. Biogen shares were not active in premarket trade. ...
This could indicate that investors who seek to profit from falling equity prices are not currently targeting BIIB. Over the last one-month, outflows of investor capital in ETFs holding BIIB totaled $335 million.